Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover PK comparison of inhaled mometasone furoate versus QMF149 in children with asthma
2020-002036-78Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indacaterol and mometasone in asthma, sponsored by Novartis. Primary endpoint: Maximum observed mometasone furoate plasma concentration. Started Dec 2020; status: completed.
02
Drugs
indacaterolmometasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2020-002036-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002036-78.